How to interpret the results of antimicrobial susceptibility testing – what to do next? Mi Suk Lee, MD. Division of infectious Diseases Kyung Hee University.

Slides:



Advertisements
Similar presentations
TREATMENT FOR SUPERIMPOSED PSEUDOMONAS AERUGINOSA INFECTION.
Advertisements

Monotherapy Versus Combination Therapy
East Texas Medical Center – Tyler Annual Physician Education MDRO -Multidrug-Resistant Organisms- Revised: April 2013.
Edward L. Goodman, MD Core Faculty Hospital Epidemiologist June 27, 2013.
The Resistance Problem PRSP = Penicillin Resistant Strep. pneumoniae QRSP = Quinolone Resistant Strep. pneumoniae MRSA = Methicillin Resistant Staph.
Choosing Antimicrobials in Special Situations. Additional considerations in making a final antibiotic selection Site of action – (Will the antibiotic.
The Increasing Public Health Exigency of Antimicrobial Resistance Alfred DeMaria, Jr., M.D. Massachusetts Department of Public Health.
Emerging Antimicrobial Resistance in Texas The new ESBLs.
2009 CLSI M100-S19 Update Nebraska Public Health Laboratory.
Antimicrobial Susceptibility Testing – Part II
Lecture 3 Antimicrobials and Susceptibility tests Dr. Abdelraouf A. Elmanama Islamic University-Gaza Medical Technology Department.
Bacterial Physiology (Micr430) Lecture 10 Macromolecular Synthesis: Cell Wall (Text Chapter: 11)
Welcome to the CDS Workshop Jeanette Pham Syd Bell Hobart 2011.
Plate 1a: Staphylococcus aureus resistant to penicillin (P0.5) only. Note the annular radius of the zone of inhibition of 9.5 mm around the cefoxitin (FOX.
Antibiotics Review 10 August :39 AM.
ANTIBIOTICS.
Antimicrobial Susceptibility Testing (AST)
Beta-lactam antibiotics - Cephalosporins
Resistance to  -lactam antibiotics within the Enterobacteriaceae Paul D. Fey, Ph. D. University of Nebraska Medical Center.
Dave Warshauer, PhD, D(ABMM)
COL Helen Viscount, PhD, D(ABMM) LTC Steven Mahlen, PhD, D(ABMM)
Culture and Sensitivity Helping the Infection Preventionist Interpret Antibiograms Walter Phillips, BS, MS, PhD Director of Microbiology TriStar Healthcare.
Warren S. Joseph, DPM, FIDSA Roxborough Memorial Hospital, Phila., PA
CHOICE OF ANTIBIOTICS IN THE VIEW OF DEVELOPING ANTIBIOTIC RESISTANCE Dr. Jolanta Miciulevičienė Vilnius City Clinical Hospital National Public Health.
MDR Organisms in Holy Family Hospital Rawalpindi
Methods Revised Abstract Methods Results TP-271 is a Potent, Broad-Spectrum Fluorocycline with Activity Against Community-Acquired Bacterial Respiratory.
Beta lactam antibiotics & Other cell wall synthesis inhibitors
Antibiogram panel Designing
Methicillin-resistant Staphylococcus Aureus - MRSA - Sharon Walker, RN, BPS Ingham County Health Department.
Clinical Cases Beta-Lactam Answers. Case 1 What antibiotic would you recommend for intravenous therapy in a 40yo BM with a Staphylococcus aureus (MSSA)
Microbiology Antimicrobial Susceptibility Testing – Part I Karen Honeycutt, M.Ed., MT(ASCP)SM CLS 418 Clinical Microbiology Student Laboratory Session.
Ceftazidime resistance in a Salmonella enterica serotype Bareilly in Ireland N.DeLappe, D Morris, C.O’Hare, E.Costello, G.Corbett-Feeney and M.Cormican.
“Emerging infections, the re-emergence of infectious diseases previously considered to be under control, and the alarming trend of antibiotic resistance….require.
Using Nursing Home Antibiograms To Improve Antibiotic Prescribing and Delivery Training Slides for Prescribing Clinicians Comprehensive Antibiogram Toolkit.
Nebraska Public Health Laboratory 2008 CLSI M100-S18 update Paul D. Fey, Ph.D. Associate Professor/Associate Director Josh Rowland, M.T. (ASCP) State Training.
Antimicrobial Resistance patterns among nosocomial gram negative bacilli by E-test and disc diffusion methods in Sina and Imam Hospital.
김의종(집필대표), 강정옥, 김미나, 김민중, 김성일, 이경원, 이도현, 이장호, 이남용, 이창규, 신종희, 장철훈, 최혜심
Common ID Syndromes March 2014.
Listing Antimicrobial Resistant Pathogens of Public Health Importance Implications for Drug Development Listing Antimicrobial Resistant Pathogens of Public.
DENS 521 Clinical Dental Therapeutics
Hospital Acquired Pneumonia(HAP): is defined as a pneumonia which occurs after 48 hours of admission to hospital. Hospital Acquired Pneumonia(HAP): is.
Bacterial Resistance in China
Antimicrobial Resistance in Streptococcus pneumoniae Implications for Prescription Drug Labeling John H. Powers, MD Lead Medical Officer Antimicrobial.
4 th Lecture By Abdelkader Ashour, Ph.D. Phone: DENS 521 Clinical Dental Therapeutics.
Supplemental testing methods
EARS-Net data on Antimicrobial Resistance in Ireland, Q3 2015
MICROBIOLOGICAL EPIDEMIOLOGY OF RESPIRATORY SPECIMENS IN ICU PATIENTS Dr Farooq Cheema, Dr Waseem Tariq, Dr Raja Ishtiaq, Dr Tabassum Qureshi, Dr Vincent.
Dr. Laila M. Matalqah Ph.D. Pharmacology
Strategies in the Selection of Antibiotic Therapy in the ICU Mazen Kherallah, MD, FCCP King Faisal Specialist Hospital & Research Center.
How to interpret the results of antimicrobial susceptibility testing – what to do next? Mi Suk Lee, M.D. Division of infectious Diseases Kyung Hee University.
4/28/2017 AST.
Using Nursing Home Antibiograms To Improve Antibiotic Prescribing and Delivery Training Slides for Nursing Home Nurses Comprehensive Antibiogram Toolkit.
PRINCIPLES OF ANTIBIOTIC THERAPY
Principles of Medical Science Pharmacology Review
MRSA, ESBLs and Carbapenem Resistance
Cephalosporins Four Generations! Bactericidal & Time-Dependent!
Current Status of Antimicrobial Resistance
N°XXXX Rapid detection of extended-spectrum BETA-lactamase producing Enterobacteriaceae from urine using the ESBL NDP test Patrice Nordmann, Laurent Poirel,
The Laboratory diagnosis and susceptibility testing of meticilline-resistant staphylococcus aureus By: Maj Anthere Murangwa, MSC Medical Microbiologist.
EARS-Net data on Antimicrobial Resistance in Ireland, Q
The Role of the Microbiology Laboratory in AMS programs
Antimicrobial Spectrum of Activity Visual Learning Exercises (“Flower Diagrams”) This work is licensed under the Creative Commons Attribution-NonCommercial-
Cell wall inhibitor Cephalosporins Dr. Naza M. Ali Lec D
Antibiotic Resistance
Clinico-Pathological Conference (CPC) Meet
Pharmacology of Cephalosporins: General Overview
Antibiotics sensitivity of microorganism causing nosocomial infections
In the Name of GOD.
19/ژانويه/17
TRAINING PRESENTATION
Presentation transcript:

How to interpret the results of antimicrobial susceptibility testing – what to do next? Mi Suk Lee, MD. Division of infectious Diseases Kyung Hee University Medical Center Mar. 20 th

What is antimicrobial susceptibility test? MIC by CLSI (Clinical and Laboratory Standards Institute) * National Committee for Clinical Laboratory Standards (NCCLS)

Choose of appropriate antibiotics Site of infection Immune status, etc Antimicrobial susceptibility test Host BacteriaAntibiotics

Prerequisite for interpretation G(+) or G(-) ? From what specimen ? Consistent with clinical symptom & sign ? Which antibiotic is specific to the recovered organism? Resistant to antibiotics ?

Prerequisite for interpretation G(+) or G(-) ? 1. Can exclude antibiotics ineffective for G(+) or G(-) from the list of treatment. 2. For G(+) : Aminoglycoside, aztreonam, FQ (ciprofloxacin, ofloxacin) can be excluded. 3. For G(-) : Glycopeptide (vancomycin, teicoplanin) can be excluded.

Prerequisite for interpretation From what specimen ? 1. All that glitter is not gold! – Because we human beings are not completely clean. – normal flora…. 2. Specimens normally sterile  Blood, CSF 3. Sputum, Stool…  low reliability

Prerequisite for interpretation Consistent with clinical symptom & Sign? 1. True infection 2. Colonization 3. Contamination during sampling specimens

Prerequisite for interpretation Which antibiotic is specific to the recovered organism? 1. You don’t have to interpret every antibiotic in the culture report list. 2. Knowing a few antibiotics specific to the recovered organism  That’s enough.

Prerequisite for interpretation Resistant to antibiotics ? 1. The interpretation of resistance is not simple. - oxacillin R in staphylococci  mean ‘do not use  -lactams’ - imipenem R in P. aeruginosa  consider R in FQs, AGs - any 3 rd cepha. or aztreonam R in G (-)  consider ESBL 2. You don’t have to know the all mechanism of resistance, but knowing resistance is mandatory.

What will be discussed? A brief review of sensitivity test  not in detail The meaning of S, R, I. Interpretation of report for individual organism We are often in the dilemmatic situation. – How should we solve these dilemma? – Although there’s not always correct answer…

Sensitivity test Dilution method – Agar dilution – Broth dilution

Sensitivity test Disk diffusion method – Diameter of inhibitory zone  Inversely correlated with the log 2 MIC – Easy to perform, but cannot apply to slow, fastidious organisms or anaerobes – Limited to Staphylococci spp., Enterobacteriaceae, Pseudomonas, Acinetobacter.

Sensitivity test E (epsiolmeter)-test – For fastidious grower such as some streptococci spp., Hemophilus influenzae, Neisseria gonorrheae, Streptococcus pneumoniae. – For anaerobes – Convenient, but costs too much.

Sensitivity test Automated – Microscan – Vitek

Report of Sensitivity “S” Sensitive : Isolates may be appropriately treated with usual dosage “R” Resistant : Predicting possible failure of the tested antimicrobial agent “I” Intermediate – or moderately susceptible

Conflicting decision when you meet “I” organism Increase the dosage of the antibiotics? Discard the antibiotics and choose an alternative one? My opinion  Rather not use it unless there’s no alternative.

Main clinically significant bacterial species you have to know G (-) – Pseudomonas – Non-pseudomonas : enterobacteriaceae G (+) – Staphylococcus – Streptococcus

G (-): ESBL-producer or not ? Extended spectrum  -lactams (oxyimino-  -lactams)  High affinity to PBP, stable to  -lactamase  Ceftazidime, ceftriaxone, cefotaxime, aztreonam, cefpodoxime ESBL (extended spectrum  -lactamases)  Hydrolyze oxyimino-  -lactams  Inhibited by clavulanate  No action to carbapenem or cephamycin  TEM, SHV, OXA group

G (-) Escherichia coli The most common cause of UTI & Sepsis Mainly intrinsic resistance & infection – In the bowel & translocation to the systemic circulation – Plasmid mediated  -lactamase : TEM-1 in 80% resistant to ampicillin, 1 st generation cephalosporins

Escherichia coli

Escherichia coli - ESBL Screening : Cefpodoxime 4 ug/mL Ceftazidime 1 ug/mL Confirm : Double disk synergy test

G (-) Klebsiella species A very tough guy !  can survive in the toughest environment. SHV-1  -lactamase producing ESBL : mediated via plasmid Patients at risk – Prolonged hospitalization, prolonged use of antibiotics – Immunocompromised host Can be transmitted via hands

Klebsiella pneumoniae

G (-) E. coli & Klebsiella If ESBL-producer,  Do not use ceftazidime, ceftriaxone, cefotaxime, aztreonam.  Double disk synergy test for confirmation

G (-) E. coli & Klebsiella - ESBL Use another one #Cephamycin (cefotetan, cefoxitin) Risky ! #  -lactam/  -lactamase inhibitor Half & half (no effect to ampC  -lactamase) #Non-  -lactam antibiotics (quinolone, aminoglycoside) Reasonable, but few clinical supporting data #4 th generation cephalosporin Half & half #Carbapenem : recommendable

G (-) Pseudomonas aeruginosa Widespread Can adapt themselves very well to any environment Opportunistic Outbreak in ICU Can be found in medical device, sink, disinfectant, vaporizer, bath, suction device, jelly or ointment, lotion, etc.

G (-) Pseudomonas aeruginosa Resistant to penicillin, cephalosporin, tetracycline, chloramphenicol, sulfonamide Sensitive to anti-pseudomonal cephalosporin (ceftazidime, sulperazone), aminoglycoside, qunolone, carbapenem Imipenem-resistant organism  recently emerging problem

G (-) P. aeruginosa Sensitive to ceftazidime, aminoglycoside, FQ?  Ignore ceftriaxone, cefotaxime, ceftizoxime  Ignore 1 st & 2 nd cephalosporins If not sensitive, how about imipenem? Avoid monotherapy ; Use antibiotics in combination (eg. Ceftazidime + AMK)

Pseudomonas aeruginosa

Multi-drug resistant P. aeruginosa

Ubiquitous in environment - 25% in skin of healthy outpatients - 7% in pharynx, 45% in tracheostomy sites Intrinsically resistant to many antibiotics Step 1: clinically significant? - Insignificant in most cases G (-) Acinetobacter spp.

Step 2 : resistant to piperacillin & ceftazidime? - Natural resistance to amp, amox, AMX/CLAV, 1 st gen. cephalosporins - Hyperproduction of chromosomal AmpC + altered porin proteins : Resistant to β-lactams except carbapenems Step 3 : resistant to imipenem? - Decrease in outer membrane protein or altered PBPs - Carbapenem-hydrolyzing enzymes : VIM-2 (Korea) Step 4 : resistant to quinolones? - Naturally less susceptible to ciprofloxacin than other genera, have MICs close to the breakpoint concentration G (-) Acinetobacter spp.

Pan-drug resistant A. baumannii Overall 30-day mortality 49% Portal of entry : 80% resp. tract Treatment : colistin, polymyxin B, high dose amp/sulb, ± RFP

G (+) Staphylococcus spp. Living on the skin MRSA = oxacillin-resistance # The meaning of oxacillin-resistance  You cannot use any  -lactams !  Only glycopeptide (vancomycin, teicoplanin) is effective. # Alteration of penicillin binding protein (PBP) # Controlled by mecA gene # Nosocomial in most cases # Person-to-person  the importance of hand washing

G (+) Staphylococcus spp. Step 1 : From what specimen ? Is it real ? Step 2 : Resistant to Oxacillin ? Step 3 : If not, Resistant to Penicillin ?

G (+) Staphylococcus spp. Step 1 : From what specimen ? Is it real ?  From blood or CSF ?  Any possibility of contamination even if isolated from blood ?  Consistent with the patient’s symptom & sign ?

G (+) Staphylococcus spp. Step 2 : Resistant to Oxacillin ? # The meaning of oxacillin-resistance  You cannot use any  -lactams !  Only glycopeptide (vancomycin, teicoplanin) is effective. # In case of oxacillin-sensitive, but resistant to any one of aminoglycoside, other  -lactams, macrolide, tetracycline, or clindamycin  Recheck whether hidden MRSA or MRCNS. oxacillin salt agar screening (6 ug/mL) # If not, go to step 3.

G (+) Staphylococcus spp. Step 3 : If not, Resistant to Penicillin ? * If yes,  -lactamase producer.   -lactamase stable penicillin (flucloxacillin, nafcillin, cloxacillin, oxacillin)   -lactam/  -lactamase inhibitor  1 st generation cephalosporins * If no, S to both penicillin & oxacillin  Penicillins or any anti-staphylococcal antibiotics

Methicillin susceptible S. aureus

Methicillin resistant S. aureus

G (+) Enterococcus spp. Step 1 : From what specimen? Blood? Step 2 : Resistant to penicillin or AG ? Step 3 : Resistant to Vancomycin?

G (+) Enterococcus spp. Step 1 : From what specimen ? Blood ? * From stool or urine  Ignore! * Recovered with other organisms (mixed)  Ignore! * From blood  Prepare for trouble! Why ?  Probability of truly virulent strain is very high.  Survivor from the bowel jungle !  Acquiring virulence during the process of invasion into blood stream from bowel.

G (+) Enterococcus spp. Born to be resistant to lots of antimicrobials (esp. cephalosporins) Vancomycin-resistant enterococcus (VRE) – VanA, VanB, VanC1/C2/C3, VanD – Can be transferred to other organisms & other species – What if it is transferred to MRSA ?  Nightmare !

G (+) Enterococcus spp. Contact isolation & Hand washing !!

G (+) Enterococcus spp. Step 2 : Resistant to penicillin or AG ? * Ignore any cephalosporins * If penicillin-sensitive  not producing  -lactamase - Ampicillin, amoxicillin, unasyn, augmentin, piperacillin, etc - Combination with AG if not highly resistant to AG * If penicillin-resistant - Vancomycin + AG if not highly resistant to AG

G (+) Enterococcus spp. Step 3 : Resistant to vancomycin ? – If not from blood, ignore !  infection control – If you’re sure that that guy is a truly virulent strain, Almost nothing to give. That’s real… Quinupristin/dalfopristin (synercid)?, Oxazolidinone (linezolid, eperzolid), Tigecycline, daptomycin, etc Teicoplanin, if VanB phenotype (a lucky case)

Penicillin susceptible E. faecium

VSE faecium

VRE faecium * Synercid : only effect to E. faecium

G (+) Streptococcus pneumoniae Step 1 : Resistant to penicillin or oxacillin? Step 2 : If yes, also resistant to 3 rd generation cephalosporins? Step 3 : From what specimen?

G (+) S. pneumoniae Step 1 : Resistant to penicillin or oxacillin? * See for resistance to oxacillin * If sensitive to oxacillin  Happy end. S to penicillin & 3 rd generation cephalosporins * If resistant to oxacillin  Go to step 2. R to penicillin, but ?? to 3 rd gen. cephalosporins Check MIC of penicillin & 3 rd gen. cephalosporins

G (+) S. pneumoniae Step 2 : Resistant to 3 rd gen. cephalosporin? – If no,  Use 3 rd generation cephalosporin – If yes,  Add Vancomycin to the 3 rd generation cephalosporin.

Streptococcus pneumoniae - PSSP * Penicillin MIC : S  0.06, I 0.1-1, R  2

Streptococcus pneumoniae - PRSP * Penicillin MIC : S  0.06, I 0.1-1, R  2

* Ceftriaxone/cefotaxime MIC in S. pneumoniae (by E-test) SIR CNS   2 2 Non-CNS  1 2  4 4 * Not available in KHMC

G (+) S. pneumoniae Step 3 : From what specimen? * From blood (with pneumonia) * From CSF  consider BBB penetration

Pneumococcal pneumonia when in vitro susceptibilities are known PSSP (PCN MIC  0.06) – Primary : penicillin-G 1 mU q 4 h or ampicillin 1 g q 6 h – Alternative : cefuroxime, cefotaxime/ceftriaxone, macrolide PRSP (PCN MIC 0.1-2) – Primary : penicillin-G 2 mU q 4 h or ampicillin 2 g q 6 h – Alternative : cefotaxime/ceftriaxone, macrolide PRSP (PCN MIC  4) – Primary : continue with initial empiric therapy if clinically satisfactory – Alternative : imipenem, macrolide, vancomycin, new FQ – Vancomycin not routinely recommended for CAP caused by PRSP

Pneumococcal meningitis when in vitro susceptibilities are known Kaplan SL, et al. Clin Microbio Rev 1998;11:628 *  2

G (+) Streptococcus spp. viridans streptococci  Penicillin-resistance or not ?  in fact, rare Streptococcus pyogenes  No sensitivity test at all because there’s been no report of  -lactam resistance Streptococcus agalactiae  Penicillin-resistance or not?

Viridans Streptococci Usually contaminant If persistent bacteremia  consider infective endocarditis If PCN MIC  4 ug/mL  use vancomycin (very rare)

Streptococcus pyogenes

Dilemma, Dilemma.. ?

Dilemma 1. Positive blood culture. Is That Real? Even in the febrile patient. Especially coagulase (-) staphylococci (CNS) The possibility of contamination : 2~3% Any guideline for discriminating the true from false ?

Dilemma 1. Positive blood culture. Is That Real? Tentative guideline for discrimination  The culprit organism - CNS, Bacillus spp., Corynebacterium spp., Micrococcus spp., P. acnes, viridans streptococci, S. maltophilia, C. perfringens  How long did it take to grow ? - If longer than 72-h, probably contamination  More than 1/4 or 1/6 bottles? - (exception) immunocompromised pt, prosthetic device.  Repeated isolation of the same organism from a sterile specimen other than blood.

Dilemma 2. Positive sputum culture. Is That Real? The sputum is the most unreliable specimen. Dilemma in the Dx. of nosocomial pneumonia. Protected BAL

Dilemma 3. Mixed culture. Is That Real? Commonly seen in the urine specimen. In most cases  not true. Exception : from abscess

Dilemma 4. What if resistant to all antimicrobials? Frankly speaking … Nobody Knows !

My opinion – somewhat subjective  Check if the specimen is a significant one : - normally sterile or not ?  Recheck sensitivity - If the result is sensitive  Thank God ! - If intermediate  increase the dosage.  Simultaneously, try another new antibiotics. (state-of-the-art) Dilemma 4. What if resistant to all antimicrobials?

Knowing is not enough ; we must apply. Willing is not enough ; we must do. by Goethe said